SCHEMBL12788710

SCHEMBL12788710

Cc1nc2ccc(N(C)C(=O)c3ccccc3)cc2c(=O)n1C(c1ccccc1)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ CASP3 P42574 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ SENP8 Q96LD8 1/20 0.39
▸ SENP7 Q9BQF6 1/20 0.39
▸ SENP6 Q9GZR1 1/20 0.39
▸ KMT2A Q03164 3/20 0.38
▸ HPGD P15428 3/20 0.38
▸ HTT P42858 2/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ ITK Q08881 4/20 0.38
▸ INSR P06213 2/20 0.38
▸ KDM4E B2RXH2 3/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.37
▸ PDE10A Q9Y233 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12788332 0.85 PDE3B (0.46) RAB9AKDM4EALDH1A1
SCHEMBL12788335 0.84 BRD4 (0.45) LMNARAB9ASMN1; SMN2KMT2AHPGD
SCHEMBL12788859 0.84 L3MBTL1 (0.55) LMNANPC1TP53RAB9ASMN1; SMN2
SCHEMBL12788888 0.83 LMNA (0.41) LMNANPC1RAB9AHPGDKDM4E
SCHEMBL12788546 0.83 ALDH1A1 (0.37) LMNARAB9AKMT2AHPGDHTT
SCHEMBL12847202 0.83 ALDH1A1 (0.37) LMNARAB9ASMN1; SMN2KMT2AHPGD
SCHEMBL12788926 0.82 CHEK2 (0.44) LMNAKMT2AHPGDMEN1KDM4E
SCHEMBL12847300 0.81 GFER (0.38) LMNANPC1TP53RAB9ASMN1; SMN2
SCHEMBL12788826 0.81 POLB (0.41) LMNATP53RAB9AHTTKDM4E
SCHEMBL12788525 0.81 KDM4E (0.41) RAB9ASMN1; SMN2KMT2AHPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2297117-B1 BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS MERCK SHARP & DOHME (US) 2012-10-31 — — EP disclosed
US-20110065671-A1 BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS MERCK SHARP & DOHME CORP. 2011-03-17 — — US disclosed
US-20110065671-A1 BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS MERCK SHARP & DOHME CORP. 2011-03-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065671-A1 BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS GPR119, GPR39, GPR65 LMNA 3472/4885NPC1 637/4885TP53 4492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback